Related Experiment Videos
Malignant melanoma: microstages and individualized therapy.
The Australian and New Zealand Journal of Surgery
|June 1, 1978
Summary
Malignant melanoma prognosis depends on clinical stage and microstage, with subungual-volar melanoma being a high-risk exception. Treatment for Stage I melanoma should be individualized based on risk factors.
Area of Science:
- Oncology
- Dermatology
- Surgical Pathology
Background:
- Malignant melanoma prognosis is primarily determined by clinical stage and microstage.
- Melanomas are categorized as low-risk or high-risk based on microstage.
- Subungual-volar melanoma presents a unique prognostic challenge, often exhibiting worse outcomes regardless of microstage.
Purpose of the Study:
- To outline individualized treatment strategies for clinical Stage I malignant melanoma.
- To differentiate therapeutic approaches for low-risk versus high-risk melanomas.
- To highlight the specific considerations for subungual-volar melanoma prognosis and management.
Main Methods:
- Clinical staging and microstaging of malignant melanoma.
- Review of treatment protocols based on risk stratification.
- Analysis of prognostic factors, including tumor location.
Main Results:
- Low-risk melanoma requires wide local excision.
- High-risk melanoma necessitates regional lymph node dissection.
- Subungual-volar melanoma warrants specific therapeutic considerations due to its poor prognosis.
Conclusions:
- Individualized therapy for Stage I malignant melanoma is crucial.
- Risk stratification guides surgical intervention, including excision, lymph node dissection, and hyperthermic perfusion for extremity tumors.
- Subungual-volar melanoma requires tailored management strategies.